Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.

Kohl's is trading at a record discount to tangible book value, with deep value metrics and a 20-25% free cash flow yield. Bearish positioning in the stock is at historic highs and borrow rates are spiking. Any positive operating news could trigger a powerful short squeeze. While stock trading and business risks remain, if the U.S. consumer economy holds and a new catalyst emerges, KSS could rebound sharply toward an initial $15-20 share target.

monday.com continues to outperform the S&P 500, driven by strong enterprise momentum, expanding margins, and robust product innovation, especially in AI. Q1 FY25 saw monday growing its revenue and non-GAAP operating income by 30% YoY and 90% YoY respectively, with margins exceeding expectations by 450 basis points. Despite cautious FY25 guidance due to SMB exposure and macro uncertainty, I see long-term upside as enterprise adoption deepens as they expand their capabilities in the enterprise tier.

Alpha Modus CEO family converts $32M in preferred stock to common, signaling confidence and aligning with shareholders ahead of key growth milestones.

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate.

VALENCIA, Calif. , June 2, 2025 /PRNewswire/ -- Cunard has unveiled its latest program of extraordinary voyages with 195 new itineraries across its iconic fleet, visiting 115 destinations in 32 countries between April 2027 and January 2028.

Alpine Income Property Trust gets a buy rating for my initial coverage, as I continue my look into various types of REITs. Notables include high occupancy levels, portfolio growth and national diversification, and a tenant roster of top-tier retail names like Dick's and Walmart. Besides a solid EBITDA margin within its sector, and proven 5-year dividend growth, operating cashflow also has been positive.

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced its acquisition of Mercury Pharmacy Services in Mountlake Terrace, Washington.

During every Coach's Challenge, Chipotle will challenge fans to find a hidden keyword in a post on X for the chance to win a free entree* In response to basketball fans' frustration with lengthy replay reviews, "Chipotle Instant Freeplays" keeps the momentum going even when the game comes to a halt NEWPORT BEACH, Calif. , June 2, 2025 /PRNewswire/ -- Chipotle Mexican Grill (NYSE: CMG) today announced a new promotion called "Chipotle Instant Freeplays" ahead of the 2025 men's professional basketball championship series.

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition today announced the successful sale of approximately $71 million in Investment Tax Credits (ITCs) generated from three of its landfill-gas-to-renewable natural gas (RNG) projects. These projects, which Ameresco developed, constructed, financed, and currently operates, were placed in service in 2024. This transaction marks Ameresco's.

With Expected Second Quarter 2025 closing, Core Gaming Timing Now at a Crossroads Denver, Colorado--(Newsfile Corp. - June 2, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, provides a critical update on Siyata Mobile's (NASDAQ: SYTA) $160 million merger with Core Gaming, though a precise closing date remains under wraps. Please click here for Core Gaming Merger Notes and Analysis, or insights from the ValueScope Report.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation fo.

Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif. , June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard …

Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) TAMPA, Fla. , June 2, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned …

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.